In mice, an appetite-neuron protein called OPA1 guarded against overeating fat and obesity — and its loss hit females harder, hinting at more personalized obesity treatment.
In a six-year study of older adults, having both abdominal obesity and low vitamin D was tied to more than double the risk of death — each condition amplifying the other.
Cambridge researchers found the obesity target GIPR works through two different brain regions — explaining why drugs that switch it on or off can both curb appetite.
Whitehead Institute scientists found polyamines act as ‘storage lockers’ for iron — and draining them could poison cancer cells with their own iron.
Adding BioLife’s cell-preservation technology to its bioprocessing tools, Repligen is betting on vertical integration as cell and gene therapies scale up.
A large study of over 21,000 women found those who used estrogen-only menopausal hormone therapy had less dementia and less Alzheimer’s pathology — but it’s an association, not proof.
The partnership will use quantum algorithms to design better photosensitizers — molecules that kill tumor cells when hit with light — a task classical computers struggle with.
Yale researchers found that omega-3 and omega-6 fats can dampen natural killer cells’ tumor-fighting power in mice — via a receptor called LRP5. It’s early, and not a reason to change your diet.
The one-time gene therapy ST-920 is heading toward an FDA filing; PTC picked it up at auction after gene-medicine pioneer Sangamo filed for bankruptcy.
A large proteomics analysis of a landmark Parkinson’s study is now public, aiming to sort patients into subtypes and speed more targeted, biology-driven therapies.
Zipalertinib plus chemo so clearly slowed a hard-to-treat form of lung cancer that the trial was stopped early — setting up a fight with drugs from J&J and AstraZeneca.
Iberdomide is the first approved CELMoD — a next-generation protein degrader — cleared in a three-drug combination for multiple myeloma as early as first relapse.